Member Info for Spodulike

Anything between £12m to £120m then. Mcap around £5m, so expect fireworks in the morning. Another 100% rise if not more. :)

Sometimes companies just need a little spark to kick start a rerate to true value.

2p should be seen.

In morning.

Should blast through 1p by close of play.

If this is correct, £118m and mcap here is £4m. Oh wowser

Just WOW.

Thought we all had a common goal of just getting it back trading again?

Think the rerate has started now.

Totally agree overthelimit.

News out anytime in regards to the drilling.

Sorry Allenby Capital.

For any new investors, From Allenby Capital

From 31st Oct 2024.

'Rising zinc price creates a valuation disconnect'

'Fair value: Following the placing we have updated our valuation to take into account the

increased number of shares outstanding, the funds received, and the rise in the value of

our peer group reflecting the higer zinc prices. As a result, we have updated our fair value

to 2.2p. This is an upside of 2,103% on the current share price.'

Allensby Capital said back in October 24 that this should be valued at 2.3p.

Semnet update very soon if the RNS is anything to go by. GLA not that we need it.

'Elsewhere in London, ImmuPharma shone on the AIM market, jumping 90%. The drug discovery and development company hailed "groundbreaking advancements" in preclinical research in the autoimmune diseases space.

"We are delighted to share these significant findings from ImmuPharma Biotech. This breakthrough research confirms our confidence in P140, its future therapeutic success and also creates potential new opportunities to strengthen our intellectual property portfolio, positioning us at the forefront of innovation in autoimmune disease therapies," CEO Tim McCarthy said.

The firm is "not at this time releasing detailed data" on the findings as they are part of an ongoing expansion of its intellectual property portfolio. However, it did say the findings pave the way for "earlier and more accurate diagnostics" and make it easier to spot patients who are more likely to respond to the P140 treatment. The findings also suggest improved monitoring of treatment response.'

Still difficult to buy?

No spike, read the RNS. Unbelievable news.

Great news for patients first and foremost. Secondly,great for shareholders. Well done IMM.

Hopefully head towards 4p by end of tomorrow. GLA

Nice to see there was no large sells for a few hours. Hopefully they’ve stopped and the handbrake is off. Let’s see tomorrow if we continue to rise. GLA